804, 322 - 11 AVENUE SW, CALGARY, A0
Oncolytics Biotech Engages Baker Tilly as New Independent Auditor
Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
To Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Biotech Inc. Enters $75 Million Open Market Sale Agreement
Q1
FY 2025
Annual and Transition Report of Foreign Private Issuers
Administrative Withdrawal
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to a Registration Statement for Securities of Certain Canadian Issuers